ascorbic acid, cholecalciferol, .alpha.-tocopherol, pyridoxine hydrochloride, folic acid, cyanocobalamin, calcium corbonate, ferrous fumarate, potassium iodide, magnesium, doconexent, icosapent · ASCORBIC ACID 85 mg/1; CHOLECALCIFEROL 200 [iU]/1; .ALPHA.-TOCOPHEROL 10 [iU]/1; PYRIDOXINE HYDROCHLORIDE 25 mg/1; FOLIC ACID 1 mg/1; CYANOCOBALAMIN 12 ug/1; BIOTIN 250 ug/1; CALCIUM CARBONATE 140 mg/1; FERROUS FUMARATE 28 mg/1; POTASSIUM IODIDE 150 ug/1; MAGNESIUM OXIDE 45 mg/1; DOCONEXENT 300 mg/1; ICOSAPENT 40 mg/1 · Capsule, Gelatin Coated · Oral · Acella Pharmaceuticals, LLC
NDC 42192-0332-30 · 30 CAPSULE, GELATIN COATED in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | ASCORBIC ACID 85 mg/1; CHOLECALCIFEROL 200 [iU]/1; .ALPHA.-TOCOPHEROL 10 [iU]/1; PYRIDOXINE HYDROCHLORIDE 25 mg/1; FOLIC ACID 1 mg/1; CYANOCOBALAMIN 12 ug/1; BIOTIN 250 ug/1; CALCIUM CARBONATE 140 mg/1; FERROUS FUMARATE 28 mg/1; POTASSIUM IODIDE 150 ug/1; MAGNESIUM OXIDE 45 mg/1; DOCONEXENT 300 mg/1; ICOSAPENT 40 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Acella Pharmaceuticals, LLC | ASCORBIC ACID 10 [iU]/1; CHOLECALCIFEROL 85 mg/1; .ALPHA.-TOCOPHEROL 250 ug/1; PYRIDOXINE HYDROCHLORIDE 140 mg/1; FOLIC ACID 200 [iU]/1; CYANOCOBALAMIN 12 ug/1; BIOTIN 300 mg/1; CALCIUM CARBONATE 28 mg/1; FERROUS FUMARATE 1 mg/1; POTASSIUM IODIDE 40 mg/1; MAGNESIUM OXIDE 45 mg/1; DOCONEXENT 150 ug/1; ICOSAPENT 25 mg/1 | Aug 5, 2026 | Aug 19, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "PNV-Omega — NDC 42192-0332-30," retrieved September 3, 2026, https://drugdashboards.com/drug/42192033230.
Free to cite with attribution — see how the data is put together.